0000899243-20-031557.txt : 20201118
0000899243-20-031557.hdr.sgml : 20201118
20201118194350
ACCESSION NUMBER: 0000899243-20-031557
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201116
FILED AS OF DATE: 20201118
DATE AS OF CHANGE: 20201118
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: HENDERSON MICHAEL THOMAS
CENTRAL INDEX KEY: 0001779990
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38959
FILM NUMBER: 201326689
MAIL ADDRESS:
STREET 1: 421 KIPLING STREET
CITY: PALO ALTO
STATE: CA
ZIP: 94301
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BridgeBio Pharma, Inc.
CENTRAL INDEX KEY: 0001743881
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 421 KIPLING STREET
CITY: PALO ALTO
STATE: CA
ZIP: 94301
BUSINESS PHONE: (650) 391-9740
MAIL ADDRESS:
STREET 1: 421 KIPLING STREET
CITY: PALO ALTO
STATE: CA
ZIP: 94301
FORMER COMPANY:
FORMER CONFORMED NAME: BridgeBio Pharma LLC
DATE OF NAME CHANGE: 20180618
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-11-16
0
0001743881
BridgeBio Pharma, Inc.
BBIO
0001779990
HENDERSON MICHAEL THOMAS
C/O BRIDGEBIO PHARMA, INC.
421 KIPLING STREET
PALO ALTO
CA
94301
0
1
0
0
Chief Business Officer
Common Stock
2020-11-16
4
M
0
10000
1.05
A
277751
D
Common Stock
2020-11-16
4
S
0
10000
45.00
D
267751
D
Common Stock
2020-11-16
4
M
0
12813
A
280564
D
Common Stock
2020-11-16
4
F
0
6353
44.33
D
274211
D
Stock Option (Right to Buy)
1.05
2020-11-16
4
M
0
10000
0.00
D
2020-05-19
2029-09-24
Common Stock
10000
18282
D
Restricted Stock Units
2020-11-16
4
M
0
12813
0.00
D
Common Stock
12813
179375
D
This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 18, 2020.
Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 12,813 shares of Common Stock underlying the Reporting Person's RSUs.
The RSUs vest over approximately four years with a vesting commencement date of May 16, 2020 and have no expiration date. 6.25% of the RSUs vested on August 16, 2020 and November 16, 2020 and an additional 6.25% will vest in quarterly installments on the 16th day of each February, May, August and November thereafter, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date.
/s/ Tara Condon, Attorney-in-Fact
2020-11-18